Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 20/20 | 0.81 |
| ▸ | AVPR1A | P37288 | 9/20 | 0.81 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462474 | 0.92 | OXTR (0.77) | OXTRAVPR1AAVPR2 | |
| SCHEMBL930718 | 0.89 | OXTR (1.00) | OXTRAVPR1AAVPR2 | |
| SCHEMBL931011 | 0.87 | OXTR (0.80) | OXTRAVPR1AAVPR2 | |
| SCHEMBL930962 | 0.86 | OXTR (0.79) | OXTRAVPR1AAVPR2 | |
| SCHEMBL8259086 | 0.85 | OXTR (1.00) | OXTRAVPR1AAVPR2 | |
| SCHEMBL930910 | 0.83 | OXTR (0.77) | OXTRAVPR1AAVPR2 | |
| SCHEMBL931581 | 0.81 | OXTR (0.71) | OXTRAVPR1A | |
| SCHEMBL4455616 | 0.81 | OXTR (1.00) | OXTRAVPR1AAVPR2 | |
| SCHEMBL931105 | 0.81 | OXTR (0.73) | OXTRAVPR1AAVPR2 | |
| SCHEMBL931073 | 0.81 | OXTR (0.70) | OXTRAVPR1AAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618972-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618972-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618972-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1863795-B1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| EP-1863795-B1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20080167323-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | CALABRESE ANDREW ANTONY | 2008-07-10 | — | — | US | disclosed |
| US-20080167323-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | CALABRESE ANDREW ANTONY | 2008-07-10 | — | — | US | disclosed |
| US-20080167323-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | CALABRESE ANDREW ANTONY | 2008-07-10 | — | — | US | disclosed |
| EP-1863795-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Pfizer Limited (GB) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100557-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006100557-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167323-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | OXTR, PRLHR, KISS1R | OXTR 1/4885AVPR1A 11/4885AVPR2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.